249 related articles for article (PubMed ID: 27103788)
1. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review.
Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y
Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788
[TBL] [Abstract][Full Text] [Related]
2. Association between Retinoic acid receptor-β hypermethylation and NSCLC risk: a meta-analysis and literature review.
Li Y; Lu DG; Ma YM; Liu H
Oncotarget; 2017 Jan; 8(4):5814-5822. PubMed ID: 28008143
[TBL] [Abstract][Full Text] [Related]
3. RARβ Promoter Methylation as an Epigenetic Mechanism of Gene Silencing in Non-small Cell Lung Cancer.
Dutkowska A; Antczak A; Pastuszak-Lewandoska D; Migdalska-Sek M; Czarnecka KH; Górski P; Kordiak J; Nawrot E; Brzeziańska-Lasota E
Adv Exp Med Biol; 2016; 878():29-38. PubMed ID: 26453065
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of the relationship between RARβ gene promoter methylation and non-small cell lung cancer.
Hua F; Fang N; Li X; Zhu S; Zhang W; Gu J
PLoS One; 2014; 9(5):e96163. PubMed ID: 24796328
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review.
Guo H; Zhou S; Tan L; Wu X; Wu Z; Ran R
Oncotarget; 2017 Jan; 8(2):2550-2557. PubMed ID: 27911280
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and potential drug target of T-cadherin in NSCLC.
Wang Z; Wang B; Guo H; Shi G; Hong X
Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between RARbeta gene promoter methylation and P53 gene mutations in non-small cell lung cancer].
Tan C; Jin YT; Xu HY; Zhang CY; Zhang H; Zhang WM; Chen CM; Sun XY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):131-6. PubMed ID: 22487818
[TBL] [Abstract][Full Text] [Related]
9. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis.
Petty WJ; Li N; Biddle A; Bounds R; Nitkin C; Ma Y; Dragnev KH; Freemantle SJ; Dmitrovsky E
J Natl Cancer Inst; 2005 Nov; 97(22):1645-51. PubMed ID: 16288117
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
Wu X; Wu G; Yao X; Hou G; Jiang F
Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
Yan W; Xu N; Han X; Zhou XM; He B
Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
[TBL] [Abstract][Full Text] [Related]
15. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological significance and potential drug target of E-cadherin in NSCLC.
Zhong K; Chen W; Xiao N; Zhao J
Tumour Biol; 2015 Aug; 36(8):6139-48. PubMed ID: 25758052
[TBL] [Abstract][Full Text] [Related]
18. Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell lung cancer.
Muñiz-Hernández S; Huerta-Yepez S; Hernández-Pedro N; Ramírez-Tirado LA; Aviles-Salas A; Maldonado A; Hernández-Cueto D; Baay-Guzmán G; Arrieta O
Int J Clin Oncol; 2016 Dec; 21(6):1051-1061. PubMed ID: 27306217
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC).
Feng H; Zhang Z; Qing X; Wang X; Liang C; Liu D
Exp Mol Pathol; 2016 Feb; 100(1):109-13. PubMed ID: 26681652
[TBL] [Abstract][Full Text] [Related]
20. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
